We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

TRLS Trellus Health Plc

0.00 (0.00%)
23 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Trellus Health Plc LSE:TRLS London Ordinary Share GB00BNNFM402 ORD GBP0.0006
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.65 1.50 1.80 1.65 1.65 1.65 50,310 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Offices Of Medical Doctors 19k -6.34M -0.0392 -0.42 2.66M
Trellus Health Plc is listed in the Offices Of Medical Doctors sector of the London Stock Exchange with ticker TRLS. The last closing price for Trellus Health was 1.65p. Over the last year, Trellus Health shares have traded in a share price range of 1.65p to 9.20p.

Trellus Health currently has 161,508,333 shares in issue. The market capitalisation of Trellus Health is £2.66 million. Trellus Health has a price to earnings ratio (PE ratio) of -0.42.

Trellus Health Share Discussion Threads

Showing 51 to 70 of 325 messages
Chat Pages: 13  12  11  10  9  8  7  6  5  4  3  2  Older
Most readers will now be familiar with Trellus Health's Technology platform and intellectual property. So just as a quick reminder, the Company’s connected health solution will be enabled through an integrated suite of technology and IP to enable scalable remote access for the Company’s care team, patients, and their health care providers, which importantly is not limited to IBD.

The primary components of the Company’s connected health solution include:
(1) TrellusElevateTM platform
(2) HIPAA-Compliant telehealth platform
(3) GRITTTM resilience assessment and personalised care plans
(4) Quad4XTM risk stratifier
(5) Digital education and behavioural tools
(6) Remote patient monitoring of symptoms, biomarkers, behaviours

And to just underscore that; Trellus secured an exclusive license from ISMMS to commercialise the patentpending GRITT™ methodology across seven chronic disease categories.

While the original GRITTTM resilience assessment was developed specifically for the IBD population, the Company considers that it can be adapted to other chronic conditions with minor refinements.

The following is a sponsored article, thus it provides both a relevant flavour and notable insights into the large and rapidly developing telehealth opportunity, not to mention that part of Trellus Health's business model includes sharing healthcare savings, which even at this early stage of telehealth adoption, appears to be substantial-

The next frontier in specialty care: How telehealth is expanding its reach by making it more accessible, affordable, and higher quality

By Dr. Keith H. Bachman – Kaiser Permanente
Jun 1, 2021

Few things can impact employer health care costs like specialty care needs. This broad category of advanced medical care deals with treatment-intensive conditions such as heart disease, depression, and cancer just to name a few. So, it makes sense that employers should always take a long look at the value of any provider’s specialty care services, especially in light of rising health care costs.

But employers may be surprised to learn that there’s a new differentiating factor that can help evaluate top-notch specialty care: telehealth.

This new virtual specialty care horizon came into sharp focus during the pandemic-driven growth and consumer acceptance of telehealth over the last year—by some estimates, telehealth use jumped more than 3,000% in 2020. And consider this: prior to Covid-19, less than 40% patients with a chronic condition had a telehealth visit. That number now stands at 60%. Just as notable: 53% patients of patients with a chronic condition now say that telehealth provided the same or better quality of care as an in-person visits, versus just 28% general population.

Employers should also note a recent a Government Accountability Office study of Medicare Advantage plans revealed that telehealth services helped to save $500 million in costs. A further study by Anthem found savings of more than $200 per care interaction due to telehealth efficiencies, including helping to reduce redundant tests and unnecessary medications, all without a dip in the quality of care.

Virtual care also has the potential to greatly improve access to advanced care in rural counties, where it may otherwise be lacking. Now specialists are freed up to provide care across a wide geographic area, saving travel time and expense. And If a patient needs to move an appointment, it can be reset quickly with no need to wait till the provider’s next trip to a patient’s area.

Full story -

Ugh - I've got a naff sized position. Hardly cover the trading costs lol
Spoke to HL not applied yet but allocations were 6.5% of applications apparently
Just checked my Interactive Investors account and can now see what I got.
My £1000 pledge should have got me 2500, I got just 162, but these do now appear as tradeable.
The balance has been returned to the account as cash and so I’ve just bought £1000 worth for 70.4p

Just in case any other II holders were wondering what had happened.

Hi wan - good to see you here. In a moment of madness I didn't own EKF before the ex div in specie date for trellus so have been begun buying a stake in the open market.

TAM clearly huge - and out of interest listing market value is the same cap as renx when it listed on aim...

Trellus Health has been a long time in the making; hence the Trellus offering is already 'scientifically validated'. They have assembled (and attracted) a highly experienced leadership team which is supported by an equally impressive Scientific Advisory Board, comprising ten pre-eminent experts.

With compelling health economics and societal benefits, an attractive business model that also includes negotiated shared cost savings, rapid expected commercialisation, with initial revenue in 2021 through demonstration projects, the platform appears set for success.

With some very large companies already taking the initiative and deploying, at the employee level, their own healthcare offerings, including some that are trialling and 'demonstrating' before a wider roll-out, Trellus might indeed accelerate very quickly out of the demonstration starting blocks!

A good example of employers taking the initiative and trialling -

Amazon’s Multichannel Bid To Bring ‘Amazon Effect’ To Healthcare
28th May 2021

Those reports, in turn, follow March announcements that it will expand its telehealth service, Amazon Care, to employees in all 50 states starting this summer. It also plans to make the service available to other employers later this year. That service, as it stands now, focuses on telehealth consultations and in-home visits from nurses for a fee.

Amazon, it seems, is more determined than ever to shoulder its own push into healthcare on its own terms, with select partnerships that augment the ecosystem already in place. Earlier this year, the joint efforts between Amazon, Berkshire Hathaway and JPMorgan Chase — Haven, which sought to, among other things, make insurance benefits easier to understand — was disbanded. The platform, and the algorithm, the pricing power and the logistics and the last mile all seem, at least in Amazon’s eyes, to be enough to disrupt healthcare.

Beyond demonstration - We know that the like of Amazon has designs beyond their own employees, and after building their own lab and trialling diagnostic testing on their own employees, they will be rolling out a much wider offering, which is very likely to be diagnostic testing beyond COVID-19 -

Amazon diagnostic lab receives College of American Pathologists accreditation

Accreditation is awarded to laboratories that meet stringent requirements for quality and safety.
Amazon's diagnostics laboratory in Hebron, Kentucky, has received accreditation from the College of American Pathologists (CAP). Widely recognized as an industry gold standard, the CAP Laboratory Accreditation Program is designed to ensure laboratories meet stringent requirements and maintain the highest standards of laboratory quality, safety, and accuracy. The laboratory—which processes thousands of COVID-19 tests a day—is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), which regulate laboratory testing in the U.S.

"From day one of launching our employee COVID-19 testing program, we have focused on achieving the highest standards of quality and safety for our diagnostics laboratory," said Cem Sibay, Vice President, Amazon. "We are thrilled to receive this accreditation from the College of American Pathologists and are committed to delivering quality results and ensuring employee well-being."

Amazon received the CAP accreditation following a rigorous application and review process, including a multi-day on-site review by a CAP inspector. The inspector examined laboratory processes to ensure accuracy in diagnostic results and verified that the highest standards are in place to promote employee safety. The inspection also included a thorough review of the laboratory's quality control procedures and employee training records, in addition to interviews with technologists and laboratory management.

The Kentucky laboratory was built in response to the COVID-19 pandemic to help ensure the health and safety of our frontline employees by providing them with regular, reliable access to free COVID-19 testing. In April 2020, we quickly responded to the pandemic and began assembling a team with a variety of skills—from research scientists and program managers to procurement specialists and software engineers—to focus on supporting a comprehensive COVID-19 testing program. The initiative included building state-of-the-art diagnostic laboratories in the U.S. and UK, and ultimately creating an in-house COVID-19 testing program from scratch. Within weeks of launching, the laboratories were processing thousands of tests per day and building incremental testing capacity. The labs have now processed millions of voluntary tests from over 750,000 of our frontline employees, making Amazon a leader in employer-driven COVID-19 testing -

I completely understand that the focus was to avoid a flop and make sure that the float was successful. That said, it is obvious now (and equally would have been in advance), that demand for the shares massively outstripped supply. It seems likely that allocations for PIs will be relatively derisory and frankly not worth the effort involved - a real slog for the likes of me who could not apply other than direct with all the admin that that entailed. It was very time consuming.

Like others, I have no idea when the balance payment that I made for shares which have been scaled back will be recredited to my account. Nor do I know how many shares I was allocated last Friday. That money has been dead for over one week and counting. I do not think that PIs were treated at all well. The company (here meaning EKF as the driving force behind all of this) needs to do much better than this in the future.

The reason for the low allocation was that the Restricted Shareholder offer was limited to £0.9Million. I didn’t spot that or else I would have applied in the main placing.
Good to know they have consistency of staff! What proportion did you get?
My experience was very straight forward, having also selected the request for a call-back (rather than wait), and I subsequently received phone call a short while afterwards (within around 10 minutes). I did not need a certificate number nor an account number.
Yeah good luck with that firstly you wait 20mins to speak to someone then they simply read the offer details and then don't understand what an allocation basis is. They might help if you know the certificate number (how?) or you account number (how many people have a designated account?).
I had other commitments/engagements yesterday afternoon, otherwise I would have reminded investors of the following -

EKF Diagnostics Holdings PLC Trellus Health plc: Successful Restricted Offer

Applicants to the Restricted Offer can confirm their final allotment of shares by contacting the Link Group helpline on 0371 664 0321. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. The helpline is open between 9.00 a.m. and 5.30 p.m., Monday to Friday excluding public holidays in England and Wales. The helpline cannot provide any financial, legal or tax advice and calls may be recorded and monitored for security and training purposes.

The information on this share issue is full of holes. (They should have called it Trellis.)
thanks – I had forgotten the point. On the face of it even if the allocation is low up there is award that – on the assumption that price. The end of the lock-in – if the price at the end of the lock-in is the same as tonight's close then I have spent £530.27 to acquire a holding worth £2087.

It crosses my mind that the low allocation under the shareholders restricted offer is related to the 6 million Euro €6 million placing cap and I should have made a different broker to access the placing a larger number.

I suspected that CSD would let me participate in the shareholders restricted offer, but not the direct placing as the CSD account appears to limit placing accesses.

Learning curve

Bscuit - ".... the base value of the demerger shares", by which I assume you mean the initial 'cost' of the locked up dividend shares.

This has been published:- "The fair value per EKF share was 0.8374p. Because the investment in Trellus was made on an arm's length basis within 6 months of the dividend, the Board judged the fair value of the dividend payment to be identical to the value of the investment."
[Source: Final Results, ]

Hence the initial value of the TRLS shares was deemed to be 13.60775p (being 16.25x the value per EKF share).

Trellus health discussed on today's 'stock picking' video - starts 12mins 30secs

On ii: still showing the full allocation, no cash returned, no corporate action notification and not traceable on their system so not possible to buy electronically...

Wonder how many days it will take to get a clear picture of how many I’ve actually got!

Well I will be complaining if I don't get a decent allocation.

Lets not jump to any conclusions but the restricted offer to EKF holders was pretty small in the context of the capital raise. Obviously they can't foresee the demand but there should be a clawback mechanism whereby we get some of the institutional allocation in the case of a large oversubscription. Note that 3 of the directors of IIG have also taken £100k each of shares for their personal accounts. You have to assume they were in the placing but lets hope we have all been treated fairly.

I made an assumption. £7480 was returned which CSD put into the ISA despite funds coming from Investment account, but today funds back in investment account, but no sign of shares, which should be 1300.

We need to know base value of de-merger shares, but that’s a query to EKF company secretary.

Not a bad start to life on the markets - can't complain about a 63% premium to the float price :o))

IIG (which I also hold) have just announced a £250,000 investment in Trellus at IPO for 625,000 shares, so that's an instant £156,000 profit for them:

Chat Pages: 13  12  11  10  9  8  7  6  5  4  3  2  Older

Your Recent History

Delayed Upgrade Clock